Corvus Pharmaceuticals to Present at AACR Annual Meeting April 16

Corvus Pharmaceuticals to Present at AACR Annual Meeting April 16 – 20 in New Orleans

Tuesday, April 5, 2016 12:30 PM UTC

BURLINGAME, Calif., April 05, 2016 -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced oral and poster presentations of key preclinical data relating to certain of its drug development programs at the American Association of Cancer Research (AACR) Annual Meeting, April 16-20, 2016 in New Orleans.

Following are the specifics for Corvus’ two poster presentations:

Inhibition of Adenosine A2A Receptor (A2AR) by CPI-444 Enhances CD8+ T cell Killing of a HER-2/neu Expressing Murine Tumor

Authored by Blake A. Scott¹, Todd Armstrong², Elizabeth M. Jaffee²

Affiliations: ¹Johns Hopkins University School of Medicine, Baltimore, MD; ²Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine, Baltimore

Session Category: Experimental and Molecular Therapeutics

Session Date/ Time: Sunday, Apr 17, 1:00 PM – 5:00 PM

Location: Morial Convention Center, Halls G-J, Poster Section 17, Poster Board 1

The Adenosine A2A Receptor Antagonist, CPI-444, Blocks Adenosine-Mediated T Cell Suppression and Exhibits Anti-Tumor Activity Alone and In Combination with Anti-PD-1 and Anti-PD-L1

Authored by Stephen Willingham¹, Po Y. Ho¹, Robert Leone², Emily Piccione¹, Carmen Choy¹, Andrew Hotson¹, Joseph Buggy¹, Jonathan Powell², Richard Miller¹

Affiliations: ¹Corvus Pharmaceuticals, Burlingame, Calif.; ²Sidney Kimmel Comprehensive Cancer Research Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore

Session Category: Immunology

Session Date/ Time: Monday, Apr 18, 1:00 PM – 5:00 PM

Location: Morial Convention Center, Halls G-J, Poster Section 26, Poster Board 21

The following oral presentation will take place as follows:

Adenosine A2a Receptor (A2aR) Antagonist as a Means of Enhancing the Efficacy of Checkpoint Blockade and Adoptive T Cell Therapy

Authored by Robert D. Leone, Judson M. Englert, Chih-Hsien Cheng, Jiayu Wen, Min-Hee Oh, Im-Hong Sun, Chirag Patel, Ian A. Bettencourt, Jonathan D. Powell

Affiliation: Sidney Kimmel Comprehensive Cancer Research Center Johns Hopkins University School of Medicine, Baltimore

Session Category: Immunology

Session Date/ Time: Tuesday, Apr 19, 4:20 PM – 4:35 PM

Location: Morial Convention Center, New Orleans Theater C

To learn more about the Corvus pipeline visit http://www.corvuspharma.com/technology/.

ABOUT CORVUS PHARMACEUTICALS
Corvus Pharmaceuticals (NASDAQ:CRVS) is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T cells. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer 
[email protected]
650-900-4522

MEDIA CONTACT:
Julie Normart, W2O Group
415-946-1087
[email protected]

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Corvus Pharmaceuticals to Present at AACR Annual Meeting April 16 – 20 in New Orleans

Editor's Picks

Welcome to EconoTimes